Treating amyloid transthyretin cardiomyopathy: lessons learned from clinical trials

Treating amyloid transthyretin cardiomyopathy: lessons learned from clinical trials

An increasing awareness of the disease, new diagnostic tools and novel therapeutic opportunities have dramatically changed the management of patients with amyloid transthyretin cardiomyopathy (ATTR-CM). Supportive therapies have shown limited benefits, mostly related to diuretics for the relief from...

Full description

Bibliographic Details
Main Authors: Daniela Tomasoni, Giovanni Battista Bonfioli, Alberto Aimo, Marianna Adamo, Marco Canepa, Riccardo M. Inciardi, Carlo Mario Lombardi, Matilde Nardi, Matteo Pagnesi, Mauro Riccardi, Giuseppe Vergaro, Enrico Vizzardi, Michele Emdin, Marco Metra
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-05-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
transthyretin cardiac amyloidosis (ATTR-CA)
treatment
tafamidis
siRNA
antisense oligonucleotide
gene editing
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2023.1154594/full

Internet

https://www.frontiersin.org/articles/10.3389/fcvm.2023.1154594/full

Similar Items